Home / Middle East Pharmaceutical Industries Co. / 2024 Annual Results

Middle East Pharmaceutical Industries Co. 2024 Annual Results

Revenue

SAR 394M

Net Profit

SAR 80M

EPS

SAR 3.99

Operating Cash Flow

SAR 35M

Middle East Pharmaceutical Industries Co. (4016) reported full year 2024 revenue of SAR 394M, up 16.4% from SAR 338M in 2023. Net profit came in at SAR 80M, up 21.3% year on year. Earnings per share were SAR 3.99. The company generated SAR 35M in operating cash flow. All figures sourced from CMA-mandated XBRL filings on the Saudi Exchange, processed by Sahm Screener.

Earnings Quality

Of every SAR 1.00 in reported net profit, SAR 0.44 arrived as operating cash flow — indicating Low quality earnings with a cash conversion ratio of 0.44.

Key Financial Metrics

Metric	2024	2023
Revenue	SAR 394M	SAR 338M
Net Profit	SAR 80M	SAR 66M
Net Margin	20.3%	19.4%
ROE	21.7%	21.5%
EPS	SAR 3.99	SAR 3.29
Total Assets	SAR 527M	SAR 445M
Total Equity	SAR 368M	SAR 306M
Total Liabilities	SAR 159M	SAR 138M
Operating Cash Flow	SAR 35M	SAR 93M

Year on Year Comparison

Revenue increased by 16.4% compared to 2023. Net profit increased by 21.3%. Both revenue and profit grew — indicating expanding business.

View full company profile →

View all years:

2025 2024 2023

Financial data sourced from CMA-mandated XBRL filings published on the Saudi Exchange (Tadawul). Data processed and structured by Sahm Screener (sahmscreener.com). Updated nightly. Last updated: 2025-04-16.